Document:

EX-10.28 Supply Agreement w/Trigon Incorporated

 

EXHIBIT 10.28

EXECUTION VERSION

SUPPLY AGREEMENT

     This Supply Agreement (the “Agreement”), is made and entered into as of the last date
of execution appearing on the signature page hereto (the “Effective Date”), by and between
Trigon Incorporated, a Pennsylvania corporation, having its principal place of business in
McMurray, Pennsylvania and which operates the business division it calls “Stelkast” (“STELKAST”)
and MAKO Surgical Corp., a Delaware corporation, having its principal place of business in
Hollywood, Florida (“MAKO”). STELKAST and MAKO are sometimes referred to herein individually as a
“Party” and collectively as the “Parties.”

Recitals

     WHEREAS, STELKAST has developed a certain “Implant” (as defined below);

     WHEREAS, STELKAST and MAKO entered into that certain Binding Letter of Intent, dated April 27,
2005 in which STELKAST agreed to grant to MAKO a non-exclusive, worldwide license to certain rights
relating to the Implant (the “LOI”); and

     WHEREAS, STELKAST and MAKO have concurrently entered into that certain License Agreement
(“License Agreement”), by which STELKAST licenses MAKO certain rights to relating to the
Implant so that it may make, use and sell the Implant independently of STELKAST;

     WHEREAS, during a Transition Period (as defined below) MAKO desires to purchase from STELKAST,
and STELKAST is willing to supply, certain Products (as defined below), under the terms and
conditions of this Agreement;

     NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and undertakings
set forth herein, and other valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the Parties agree as follows:

ARTICLE I

Definitions

     1.1 An “Affiliate” of a party means an entity directly or indirectly controlling,
controlled by or under common control with that party, where control means the ownership or
control, directly or indirectly, of more than fifty percent of all of the voting power of the
shares (or other securities or rights) entitled to vote for the election of directors or other
governing authority, as of the date of this Agreement or hereafter during the Effective Period of
this Agreement. However, the entity will be considered an Affiliate only for the time during which
such control exists.

     1.2 “Agreement” means this Supply Agreement, as it may be amended from time to time.

     1.3 “CGMP Regulations” means the current good manufacturing practices (“CGMP”)
promulgated by the FDA, as amended, including those currently set out in Parts 210 and 211 of Title
21 of the Code of Federal Regulations.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 1 

 

EXECUTION
VERSION

     1.4 “Delivery Date” means a date for which delivery of Product is properly requested
in a purchase order.

     1.5 “Effective Date” has the meaning given in the preamble.

     1.6 “FDA” means the United States Food and Drug Administration.

     1.7 “First Commercial Sale” shall mean the first commercial sale by MAKO or its
Affiliates of the Product.

     1.8 “Implant,” as used in both a singular and plural context, means the unicondylar
knee implant system and all components thereof, including prostheses and related medical
instruments and surgical techniques, developed by STELKAST and used for a single procedure.

     1.9 “License Agreement” has the meaning given to it in the recitals.

     1.10 “Manufacturing Price” regarding the Product means [***] Dollars ($[***]), The
Manufacturing Price of each component of the Product is a set forth in Section 3.1 hereto.
Manufacturing Price regarding instruments used with the Product shall mean STELKAST”S actual cost
for such instruments.

     1.11 “Product,” as used in both a singular and plural context, means the Implant.

     1.12 “Product Approval” means final FDA approval to market commercially in the U.S.A.
the specified Product for use in humans

     1.13 “Site Services” has the meaning set forth in Section 4.3.

     1.14 “Specifications” means he description and specification for the Implant contained
in the specifications and technical documents relating to the manufacture, operation, use and
implantation of the Implant (including all prior versions and the most current version of it) that
are in the possession of STELKAST or its employees, representatives or agents on or before the
Effective Date, including without limitation FDA design control documents DHF, DMR (design
requirement and criteria, specified requirements, V&V, design transfer), clinical data and implant
follow-ups, and manufacturing specifications and know.

     1.15 “Transition Period” means the period between the Effective Date and the date on
which MAKO is able and ready to make and sell a unicondylar knee implant independently, under its
own label, with all necessary regulatory approvals in the United States, but in any case ending not
later than twenty-four (24) months after the Effective Date.

ARTICLE II

Sale And Purchase Of Product

     2.1 Sale and Purchase.

     2.2 During the Transition Period, STELKAST, within the limitations contained in this Article,
agrees to use best efforts to sell to MAKO such quantities of Product as MAKO may

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 2 

 

EXECUTION
VERSION

order in
accordance herewith. It is understood that STELKAST shall have the right in connection with supply
hereunder to contract with such third parties as STELKAST deems advisable to manufacture Product,
provided, however, that STELKAST shall remain fully responsible hereunder.

     2.3 STELKAST will not to solicit or supply, without the written consent of MAKO, Product to
parties to whom MAKO sells Products.

     2.4 Quantity; Forecasts.

     (a) With respect to each Product, MAKO shall deliver to STELKAST (i) at least four (4) full
calendar quarters prior to the calendar quarter in which the First Commercial Sale of such Product
is projected to occur, a forecast of MAKO’s quantity requirements for such Product for the calendar
quarter in which the First Commercial Sale of such Product is projected to occur and (ii) at least
one (1) full calendar quarter prior to the calendar quarter in which the First Commercial Sale of
such Product is projected to occur, MAKO’s firm order and Delivery Dates for such Product for such
calendar quarter and a good-faith forecast of its quantity requirements for such Product for the
next three (3) calendar quarters, provided that no forecasts or orders need be given for any period
after the term of this Agreement. Thereafter, MAKO shall deliver to STELKAST at or prior to the
end of each calendar quarter, MAKO’s firm order and Delivery Dates for such Product for the second
calendar quarter following such calendar quarter and a forecast of its quantity requirements for
such Product for the three (3) following calendar quarters. If a required forecast or order for a
quarter is not timely submitted for a Product, the immediately preceding forecast for that quarter
shall become the new forecast or order; if there is no preceding forecast for a quarter, the
forecast or order for the immediately preceding quarter shall become the forecast or order.

     (b) For each quarterly forecast of Product, the amount of any Product forecasted for delivery
in the first of the three calendar quarters forecasted shall be not less than [***] percent
([***]%) or more than [***] percent ([***]%) of the most recent previous forecast for such quarter.

     (c) MAKO’s forecasts and orders will reflect its good-faith expectations of customer demand
and MAKO will act in a commercially reasonable manner to schedule orders to avoid creating
production capacity problems for STELKAST.

     2.5 Delivery.

     (a) All Products delivered to MAKO will be F.O.B. STELKAST’s plant or other place of shipment.
STELKAST will use best efforts deliver Product within 5 days of the applicable Delivery Dates and
assist MAKO in arranging any desired insurance (in amounts that MAKO shall determine) and
transportation, via air freight unless otherwise specified in writing, to any destinations
specified in writing from time to time by MAKO. All customs, duties, costs,
taxes, insurance premiums, and other expenses relating to such transportation and delivery
will be at MAKO’s expense.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 3 

 

EXECUTION
VERSION

     (b) STELKAST will package the Products in the manner requested by MAKO. STELKAST will include
with each shipment copies of all applicable quality and testing records, which shall be in a form
acceptable for FDA submission.

     2.6 Rejection of Product in Case of Nonconformity.

     (a) MAKO may reject any portion of any shipment of Product that (i) does not conform to the
description or Specifications, (ii) is adulterated or misbranded within the meaning of the Federal
Food, Drug and Cosmetic Act (the “Act”), (iii) does not comply with an order for the
Products, or (iv) does not comply with the CGMP Regulations.

     (b) In order to reject a shipment, MAKO must (i) give notice to STELKAST of MAKO’s intent to
reject the shipment within thirty (30) days of receipt together with a written indication of the
reasons for such possible rejection, and (ii) as promptly as reasonably possible thereafter,
provide STELKAST with notice of final rejection and the full basis therefore. After notice of
intent to reject is given, MAKO shall cooperate with STELKAST in determining whether rejection is
necessary or justified. If no such notice of intent to reject is timely received, MAKO shall be
deemed to have accepted such delivery of Product. However, in the case of Products having latent
defects which upon diligent examination by MAKO upon receipt could not have been discovered, MAKO
must give notice of MAKO’s intent to reject within thirty (30) days after discovery of such
defects.

     (c) In any event, MAKO must pay for the shipment as otherwise provided herein and will be
entitled to a refund of the purchase price (together with insurance and freight charges) of
properly rejected Products at the time they are ultimately rejected, provided that if STELKAST
disputes the rejection, refund shall be made, if at all, at the time the dispute is finally
resolved. STELKAST shall notify MAKO as promptly as reasonably possible whether it accepts MAKO’s
basis for any rejection.

     (d) Whether or not STELKAST accepts MAKO’s basis for rejection, promptly on receipt of a
notice of rejection, STELKAST shall use its reasonable efforts, at MAKO’s request, to provide
replacement Product which shall be purchased by MAKO as provided in this Agreement.

     (e) Unless STELKAST requests the return to it of a rejected batch within sixty (60) days of
receipt of MAKO’s notice of rejection, MAKO shall destroy such batch promptly and provide STELKAST
with certification of such destruction. MAKO shall, upon receipt of STELKAST’s request for return,
promptly dispatch said batch to STELKAST, at STELKAST’s cost.

     2.7 MAKO’s Obligations.

     (a) MAKO agrees to ascertain and comply with all applicable laws and regulations and standards
of industry or professional conduct in connection with the use, distribution or
promotion of the Products, including without limitation, those applicable to product claims,
labeling, approvals, registrations and notifications.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 4 

 

EXECUTION
VERSION

     (b) MAKO will work diligently to establish an independent product source for Products,
including obtaining necessary FDA approvals for Products made under its authority.

     (c) For the avoidance of any doubt, MAKO has no obligation to purchase Products from STELKAST.

ARTICLE III

Price And Payments

     3.1 Price. MAKO shall pay to STELKAST the Manufacturing Price for Product purchased under
this Agreement. The Manufacturing Price for each of the Product Components is as follows:

	 	 	 	 	 
	Part	 	Cost	 
	 
	(a) Stelkast unicondylar knee; Femoral component
	 	$	[***]	 
	(b) Stelkast unicondylar knee; Inlay tibial component
	 	$	[***]	 
	(c) Stelkast Instruments
	 	 	[***]	 

     3.2 Method of Payment. All payments due hereunder to STELKAST shall be paid to STELKAST in
United States dollars in the United States not later than 45 days following the date of the
applicable invoice.

ARTICLE IV

Branding & Site Services

     4.1 Labeling. MAKO may specify, at the time of ordering, whether Products will bear a
STELKAST label or a MAKO label. If MAKO orders Products with MAKO labels, MAKO must first have
provided to STELKAST either labels suitable for placing on STELKAST’s packaging for the Products or
packaging suitable for the Products.

     4.2 Limited License. STELKAST grants to MAKO a limited, non-exclusive license to use the mark
“STELKAST” and any other trade names, trademarks and trade dress used on or in connection with
Products purchased by MAKO from STELKAST pursuant to this Agreement, to refer to the Products and
to STELKAST in connection with the marketing, advertising, distribution, sale and use of the
Products. STELKAST further grants to MAKO the right to create, reproduce, publish, and distribute
images and renderings (including photographs and video) of the Products and Packaging and any
accompanying documentation.

     4.3 Site Services. STELKAST shall provide MAKO site management support services at UPMC
Shadyside in Pittsburgh PA (the “Site Services”) when and if reasonably requested by MAKO.
Site Services shall include one or more of inventory management, billing, clinical support during
each surgical procedure, and maintenance of a service contract with hospital. STELKAST will charge
MAKO a fixed sum of $[***] per procedure performed for any and all such clinical support services
provided to MAKO. In all cases where STELKAST
provides Site Services on behalf of MAKO, STELKAST shall tender to MAKO within thirty (30)
days the net proceeds paid to STELKAST for such procedure after deducting only the Manufacturing
Price and the Site Services.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 5 

 

EXECUTION
VERSION

ARTICLE V

Termination, Rights And Obligations Upon Termination

     5.1 Term. This Agreement shall continue in effect (the “Effective Period”) until the
earlier of 24 months from the Effective Date or the end of the Transition Period.

     5.2 Termination by Mutual Agreement. This Agreement may be terminated upon mutual written
agreement of the Parties.

     5.3 Termination for Default. If either Party materially defaults in the performance of any
material agreement, condition or covenant of this Agreement and such default or noncompliance shall
not have been remedied, or steps initiated to remedy the same to the other Party’s reasonable
satisfaction, within sixty (60) days (or 30 days in the case of non-payment) after receipt by the
defaulting Party of a notice thereof from the other Party, the Party not in default may terminate
this Agreement.

     5.4 Termination of License. This Agreement will terminate automatically upon termination of
the License Agreement.

     5.5 Rights and Obligations on Expiration or Termination. Except to the extent expressly
provided to the contrary, the following provisions shall survive the termination of this Agreement:
Articles VI and VII. Any rights of STELKAST to payments accrued through termination as well as
obligations of the Parties under firm orders for purchase and delivery of Products at the time of
such termination shall remain in effect, except that in the case of termination under Section 5.3,
the terminating Party may elect whether obligations under firm orders will remain in effect and
except that STELKAST will have no obligation with respect to Delivery Dates more than 6 months
after termination.

ARTICLE VI

Representation and Warranties

     6.1 STELKAST represents, warrants and covenants to MAKO as to the following as of the
Effective Date:

     (a) When shipped to MAKO by STELKAST, the Products (i) will conform in all respects to the
Specifications, (ii) will not be adulterated or misbranded within the meaning of the Act, and (iii)
will be manufactured in accordance with CGMP Regulations. STELKAST further represents and warrants
to MAKO that, to the actual knowledge of Stelkast, on the Effective Date and any date the Products
shall be shipped to MAKO (y) the Products and their sale, marketing and use in their intended
manner will not infringe any patent, copyright or, or misappropriate any trade secrets, of any
third party, and (z) any branding or trade dress appearing on the Products, other than MAKO’s marks
and trade dress, will not cause infringement of any trademark, trade name, service mark, or trade
dress of any third party, or
constitute unfair competition or violate any rights of publicity or privacy when sold or
advertised.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 6 

 

EXECUTION
VERSION

     (b) STELKAST has the requisite institutional knowledge and commercially adequate expertise to
provide the technical assistance and clinical support services it is offering and/or pledging to
provide to MAKO under this Agreement.

     (c) Insurance. STELKAST maintains adequate insurance covering the Product (including product
liability and commercial general liability insurance), as would be acquired and maintained by a
reasonable and prudent businessperson carrying on a similar line of business, but in no case for an
amount of less than Four Million Dollars ($4,000,000) per claim and/or $5,000,000 in the aggregate
(“Adequate Insurance”). Such Adequate Insurance shall at all times during the Effective
Period and for not less than five (5) years thereafter insure MAKO, its Board of Directors,
officers, employees, agents and consultants as insured parties.

     6.2 MAKO represents, warrants and covenants to STELKAST that as of and following the Effective
Date MAKO maintains adequate insurance (including product liability and commercial general
liability insurance), as would be acquired and maintained by a reasonable and prudent
businessperson carrying on a similar line of business, but in no case for an amount of less than
Adequate Insurance. Such Adequate Insurance shall at all times during the Effective Period and for
not less than five (5) years thereafter insure STELKAST, its Board of Directors, officers,
employees, agents and consultants as insured parties.

     6.3 Disclaimers.

     (a) Other than the representations, warranties and covenants expressly made in this Agreement,
neither Party, nor any of its Affiliates, make any representations or extend any warranties of any
kind, express or implied. STELKAST and MAKO each disclaim all implied warranties, including
without limitation warranties of merchantability, and fitness for a particular purpose.

     (b) EXCEPT IN CONNECTION WITH INDEMNIFICATION FOR DAMAGES AWARDED FOR THIRD PARTY CLAIMS OF
PERSONAL INJURY PURSUANT TO ARTICLE VII, OR AS EXPRESSLY PROVIDED OTHERWISE IN THIS AGREEMENT, IN
NO EVENT WILL MAKO OR STELKAST BE LIABLE FOR ANY PUNITIVE, INDIRECT, SPECIAL, INCIDENTAL OR
CONSEQUENTIAL DAMAGES OF ANY KIND WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT UNDER ANY
THEORY, INCLUDING CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY.

ARTICLE VII

Indemnification

     7.1 Indemnification. STELKAST agrees to indemnify in respect of, and hold MAKO and its
officers, directors, employees and agents harmless against, any and all damages, claims,
deficiencies, losses, including taxes, and all expenses (including interest, penalties, and
reasonable attorneys’ and accountants’ fees and disbursements but reduced by any tax savings,
benefits or offsets to which any party shall be entitled directly or indirectly by reason thereof)
(collectively “Damages”) resulting from any misrepresentation, breach of warranty, or
failure to perform any covenant or agreement on the part of STELKAST under this Agreement.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 7 

 

EXECUTION
VERSION

STELKAST further agrees to indemnify in respect of, and hold MAKO and its respective officers,
directors, employees and agents harmless against, all Damages resulting from personal injuries and
deaths from the use of Products manufactured, produced, sold or marketed by STELKAST or its
Affiliates, except to the extent such injury or death results from (1) the negligence, gross
negligence or intentional misconduct of MAKO and its employees, officers and directors or any other
persons using the Products, or (ii) a change to the Product after it has been manufactured by
STELKAST or the use of a technique with respect to the Product other than a technique developed
and/or endorsed by STELKAST.

     7.2 MAKO agrees to indemnify in respect of, and hold, STELKAST and its officers, directors,
employees and agents harmless against, any and all Damages resulting from any misrepresentation,
breach of warranty, or failure to perform any covenant or agreement on the part of MAKO under this
Agreement. MAKO further agrees to indemnify in respect of, and hold STELKAST and its respective
officers, directors, employees and agents harmless against, all Damages resulting from personal
injuries and deaths from the use of any products other than the Products that are manufactured,
produced, sold or marketed by MAKO or its Affiliates, except to the extent such injury or death
results from the negligence, gross negligence or intentional misconduct of STELKAST and its
employees, officers and directors.

ARTICLE VIII

Miscellaneous Provisions

     8.1 Assignment. Neither Party may assign or delegate its obligations under this Agreement
absent the written consent of the other party, except that no such consent will be required for
succession by merger, consolidation, sale of all or substantially all of the assets, or change of
control, but only if the assignee, successor or surviving entity agrees to be bound in writing to
all of its terms and conditions. This Agreement will be binding on successors in interest and
permitted assigns. An assignment other than as expressly permitted by this Section 8.1 will be
void and shall constitute a material breach of this Agreement.

     8.2 Notices. All notices and other communications which are required or which may be given
under the provisions of this Agreement will be in writing and may be delivered (a) personally, (b)
by facsimile transmission, (c) expedited delivery service with proof of delivery or (d) sent by
United States Mail, postage prepaid, registered or certified, return receipt requested, addressed
as follows:

	 	 	 	 	 
	 

	 	If to STELKAST:
	 	Trigon Incorporated
	 

	 	 	 	200 Hidden Valley Road
	 

	 	 	 	McMurray, PA 15317
	 

	 	 	 	Fax: (724) 941-5984
	 

	 	 	 	Attention: Peter N. Stephans
	 
	 	 	 	 
	 

	 	If to MAKO:
	 	MAKO Surgical Corp.
	 

	 	 	 	2901 Simms St.
	 

	 	 	 	Hollywood, FL 33020
	 

	 	 	 	Fax: (954) 927-0446

Attention: General Counsel

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 8 

 

EXECUTION
VERSION

or to such other address designated by the Parties as provided above. Any such notice will be
deemed to have been given either at the time of personal delivery or, in the case of delivery
service or mail, as of the date of first attempted delivery at the address and in the manner
provided herein.

     8.3 Choice of Law. THIS AGREEMENT WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE
LAWS OF THE STATE OF DELAWARE, EXCLUSIVE OF ITS CONFLICTS OF LAW PRINCIPLES.

     8.4 Captions. The captions, headings, and arrangements used in this Agreement are for
convenience only and do not in any way affect, limit, amplify, or modify its terms and provisions.

     8.5 No Strict Construction. This Agreement is the result of substantial negotiations among
the Parties and their counsel and has been prepared by their joint efforts. Accordingly, the fact
that counsel to one Party or another may have drafted this Agreement or any portion of this
Agreement is immaterial and this Agreement will not be strictly construed against any Party.

     8.6 Severability and Reformation. Wherever possible, each provision of this Agreement will be
interpreted in such manner as to be effective. If any provision of this Agreement is held to be
illegal, invalid, or unenforceable under present or future laws effective during the term of this
Agreement, such provision will be fully severable and this Agreement will be construed and enforced
as if such illegal, invalid, or unenforceable provision had never comprised a part of this
Agreement, and the remaining provisions of this Agreement will remain in full force and effect.
Furthermore, in lieu of each such illegal, invalid, or unenforceable provision, there will be added
automatically as a part of this Agreement a provision as similar in terms to such illegal, invalid,
or unenforceable provision as may be possible and be legal, valid, and enforceable; provided,
however, that, if any such change will materially diminish the practical realization of the
benefits intended to be conferred to any Party to this Agreement, such Party may terminate this
Agreement upon written notice to each other Party within 30 days after learning such change has
been effected.

     8.7 Consents; Waivers. Any consent or approval required as a condition to an action under
this Agreement will be effective only (a) if in writing and signed by the Party whose consent is
sought, (b) with respect to the specific matter made the subject to such consent or approval (and
no other matter), and (c) for the specific instance(s) expressly set forth in such consent or
approval (and no earlier or subsequent instances). Any Party may waive any condition, covenant,
term, or provision of this Agreement, but any such waiver will be effective only (a) if in writing
and signed by the Party sought to be bound by such waiver, (b) with respect to the specific
condition, covenant, term, or provision expressly made the subject to such waiver (and no other
condition, covenant, term, or provision), and (c) for the specific instance(s) expressly set forth
in such waiver (and no earlier or subsequent instances). Without limiting the foregoing sentence,
none of the following will constitute a waiver of the rights of a Party to this Agreement to demand
exact compliance with the conditions, covenants, terms, and provisions of
this Agreement: (a) a failure of such Party to exercise any power reserved to it in this
Agreement; (b) a failure of such Party to insist upon compliance by any other Party to this
Agreement with any condition, covenant, term, or provision in this Agreement; (c) a delay,
forbearance, or

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 9 

 

EXECUTION
VERSION

omission of such Party to exercise any power; or (d) any custom or practice of the
Parties at variance with the terms of this Agreement. The consent or approval of any Party to this
Agreement with respect to the act of any other Party to this Agreement will not be deemed to waive
or render unnecessary consent to or approval of any subsequent similar act. Subsequent acceptance
by a Party to this Agreement of any performance due to it under this Agreement will not be deemed
to be a waiver by such first Party of any preceding breach by any other Party of any terms,
provisions, covenants, or conditions of this Agreement. No act or conduct of or by MAKO under this
Agreement, including any payment of a royalty, shall be evidence, or deemed an admission or
suggestion, that any product manufactured, licensed, or distributed by MAKO infringes the Licensed
IP Rights or any other intellectual property right.

     8.8 Force Majeure. Neither Party will be in default or otherwise liable for any delay in or
failure of its performance under this Agreement if such delay or failure arises by any reason
beyond its reasonable control, including any act of God, any acts of the common enemy, the
elements, earthquakes, floods, fires, epidemics, riots, failures or delay in transportation or
communications, or any act or failure to act by the other Party or such other Party’s employees,
agents, or independent contractors or representatives; provided, however, that lack of funds will
not be deemed to be a reason beyond a Party’s reasonable control. The Parties will promptly inform
and consult with each other as to any of the above causes that in their judgment may or could be
the cause of a delay in the performance of this Agreement.

     8.9 Legal Costs. Each of the Parties will be responsible for its own expenses, including
legal and accounting fees of advisors, incurred in connection with the negotiation and preparation
of this Agreement. If any action is brought to enforce or interpret the terms of this Agreement
(including through arbitration), the prevailing Party will be entitled to reasonable legal fees,
costs, and disbursements in addition to any other relief to which such Party may be entitled.

     8.10 Dispute Resolution.

     (a) STELKAST and MAKO will attempt to settle any claim or controversy arising out of
this Agreement through consultation and negotiation in good faith and in a spirit of mutual
cooperation.

     (b) In the event that, after reasonable consultation, but within 30 days, the Parties
are unable to reach agreement, any claim or controversy shall be settled by arbitration
administered by the American Arbitration Association under its then current Commercial
Arbitration Rules, before a single arbitrator and judgment on any award rendered by or
finding of the arbitrator may be entered in any court having jurisdiction thereof. The
arbitrator shall have the authority to award actual money damages (with interest on unpaid
amounts from the date due), temporary injunctive relief, and reasonable attorney’s fees and
expenses, but the arbitrator shall not have the authority to award exemplary or punitive
damages, and the Parties expressly waive any claimed right to such damages. The costs of
arbitration shall be borne by the Parties in accordance
with the award of the arbitrator. If a Party fails to proceed with arbitration,
unsuccessfully challenges the arbitration award, or fails to comply with the arbitration
award, the other Party is entitled to costs, including reasonable attorney’s fees, for
having

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 10 

 

EXECUTION VERSION

to compel arbitration or defend or enforce the award. Except as otherwise required
by law, the Parties agree to maintain and agree to cause the arbitrator to maintain as
confidential all information, documents and other data of any kind or nature whatsoever
obtained during the arbitration process, including the fact that such arbitration is being
undertaken and the final award of the arbitrator.

     8.11 Integration. This Agreement sets forth the entire agreement and understanding between
the Parties as to the subject matter hereof and merges all prior discussions between them;
provided, however, that for the avoidance of doubt, this Agreement shall not affect the Parties’
obligations under the License Agreement. Neither of the Parties shall be bound by any warranties,
understandings or representations with respect to such subject matter other than as expressly
provided herein or in a writing signed with or subsequent to execution hereof by an authorized
representative of the Party to be bound thereby.

     8.12 No Partnership. Neither this Agreement, nor any terms and conditions contained herein,
will be deemed or construed to create a partnership, joint venture, other form of business
enterprise or association or cooperative arrangement, agency relationship, or franchise
relationship between the Parties or otherwise to create any liability for either Party whatsoever
with respect to the indebtedness, liabilities, and obligations of the other Party.

     8.13 Counterparts. This Agreement may be executed in any number of counterparts and will be
effective when each Party to this Agreement has executed at least one counterpart, with the same
effect as if all signing Parties had signed the same document. All counterparts will be construed
together and evidence only one agreement, which, notwithstanding the actual date of execution of
any counterpart, will be deemed to be dated the day and year first written above. In making proof
of this Agreement, it will not be necessary to account for a counterpart executed by any Party
other than the Party against whom enforcement is sought or to account for more than one counterpart
executed by the Party against whom enforcement is sought.

     8.14 Facsimile Signatures. The manual signature of any Party to this Agreement that is
transmitted to any other Party or counsel to any other Party by facsimile will be deemed for all
purposes to be an original signature.

     8.15 BASIS OF BARGAIN. EACH PARTY RECOGNIZES AND AGREES THAT THE WARRANTY DISCLAIMERS AND
LIABILITY AND REMEDY LIMITATIONS IN THIS AGREEMENT ARE MATERIAL, BARGAINED FOR BASES OF THIS
AGREEMENT AND THAT THEY HAVE BEEN TAKEN INTO ACCOUNT AND REFLECTED IN DETERMINING THE CONSIDERATION
TO BE GIVEN BY EACH PARTY UNDER THIS AGREEMENT AND IN THE DECISION BY EACH PARTY TO ENTER INTO THIS
AGREEMENT.

******

[SIGNATURE PAGE FOLLOWS]

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 11 

 

     IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed in duplicate
originals by its duly authorized representatives on the respective dates entered below.

	 	 	 	 	 	 	 
	 	 	TRIGON INCORPORATED	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Peter N. Stephans	 	 
	 

	 	Name:
	 	Peter N. Stephans	 	 
	 

	 	Title:
	 	CHMN & CEO	 	 
	 

	 	Date:
	 	9/13/05	 	 
	 
	 	 	 	 	 	 
	 	 	MAKO SURGICAL CORP.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Maurice R. Ferré	 	 
	 

	 	Name:
	 	Maurice R. Ferré	 	 
	 

	 	Title:	 	Pres & CEO	 	 
	 

	 	Date:
	 	9/13/05	 	 

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 12EX-10.29 License Agreement w/Trigon Incorporated

 

EXHIBIT 10.29

EXECUTION VERSION

LICENSE AGREEMENT

     This License Agreement (the “Agreement”), is made and entered into as of the last date of
execution appearing on the signature page hereto (the “Effective Date”), by and between Trigon
Incorporated, a Pennsylvania corporation, having its principal place of business in McMurray,
Pennsylvania and which operates the business division it calls “Stelkast” (“STELKAST”) and MAKO
Surgical Corp., a Delaware corporation, having its principal place of business in Hollywood,
Florida (“MAKO”). STELKAST and MAKO are sometimes referred to herein individually as a “Party” and
collectively as the “Parties.”

Recitals

     WHEREAS, STELKAST has developed a certain unicondylar knee implant system and components
thereof, including prostheses and related medical instruments and surgical techniques
(collectively, and as used in both a singular and plural context, “Implant”);

     WHEREAS, MAKO desires to license certain rights relating to the Implant and STELKAST is
willing to license MAKO those rights under the terms and conditions of this Agreement;

     WHEREAS, STELKAST and MAKO entered into that certain Binding Letter of Intent, dated April 27,
2005 in which STELKAST agreed to grant to MAKO a non-exclusive, worldwide license to certain rights
relating to the Implant (the “LOI”); and

     WHEREAS, STELKAST and MAKO are concurrently entering into that certain Supply Agreement, by
which STELKAST agrees to supply to MAKO commercial quantities of the Implant for resale during the
Transition Period (as defined below).

     NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and undertakings
set forth herein, and other valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties agree as follows:

ARTICLE I.

Definitions

     1.1 An “Affiliate” of a Party means an entity directly or indirectly controlling, controlled
by or under common control with that Party, where control means the ownership or control, directly
or indirectly, of more than fifty percent of all of the voting power of the shares (or other
securities or rights) entitled to vote for the election of directors or other governing authority,
as of the date of this Agreement or hereafter during the Effective Period of this Agreement.
However, the entity will be considered an Affiliate only for the time during which such control
exists.

     1.2 “Effective Date” has the meaning given in the preamble.

     1.3 “Implant” has the meaning given to it in the recitals.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 1 

 

     1.4 “Licensed Implant Methods” means surgical techniques and processes for implanting the
Implant and using associated medical instruments and equipment.

     1.5 “Licensed Technical Information” means specifications and technical documents relating to
the manufacture, operation, use and implantation of the Implant (including all prior versions and
the most current version of it) that are in the possession of STELKAST or its employees,
representatives or agents on or before the Effective Date, including without limitation FDA design
control documents DHF, DMR (design requirement and criteria, specified requirements, V&V, design
transfer), clinical data and implant follow-ups, and manufacturing specifications and know-how.

     1.6 “Licensed IP Rights” means all patents, copyrights, proprietary rights in technical
information and similar industrial and intellectual property rights throughout the world that
pertain in any respect to the Implant, and that are owned by STELKAST or that STELKAST has the
right to license as of the Effective Date.

     1.7 “Transition Period” has the meaning given to it in Section 3.3.

ARTICLE II.

Grant of License

     2.1 Grant of License to MAKO. Subject to all of the terms and conditions of this Agreement,
STELKAST grants to MAKO and its Affiliates a non-transferable (except as expressly permitted under
Section 10.1), non-exclusive, royalty-free, non-terminable and irrevocable (except as expressly
provided in this Agreement) worldwide license under the Licensed IP Rights,

     (a) to make, have made, use, offer for sale, sell, and import the Implant;

     (b) to use, disclose, reproduce, distribute, display, perform, and prepare derivatives
of Licensed Technical Information in connection with developing and manufacturing the
Implant , and to authorize others to do so on behalf of MAKO or its Affliates for the
Implant to be sold by MAKO or its Affliates;

     (c) to use, disclose, reproduce, distribute, display, perform, and prepare derivatives
of Licensed Technical Information in connection with selling, distributing, implanting,
testing and using the Implant , and to authorize others to do so;

     (d) to use the Licensed Implant Methods and to authorize others to use the Licensed
Implant Methods, in connection with the Implant.

     2.2 Sublicensing. The license granted to MAKO under Section 2.1 does not include any right to
MAKO to grant sublicenses, except that, without limiting the scope of Section 2.1, MAKO may grant
limited, non-transferable sublicenses, under the Licensed IP Rights (i) to its vendors for the sole
and limited purposes of having components made, and/or the Implant assembled on behalf of MAKO;
(ii) to its sales representatives, distributors and other sales agents to market and sell the
Implant; and (iii) to medical professional, organizations and support staff to use the Licensed
Implant Methods, Technical Information and the Implant in connection with implanting the the
Implant and patient care.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 2 

 

     2.3 No Other Licenses; No Assignments. Other than the license expressly set forth above,
neither Party is granting to the other any license or sublicense, whether by implication, estoppel
or otherwise. Except as otherwise expressly stated, nothing in this Agreement is intended to
transfer title to or other ownership interest in any intellectual property right. The foregoing
grant of sublicense does not constitute a non-infringement representation, warranty or covenant.

ARTICLE III.

Transfer of Information and Assistance

     3.1 Transfer of Technical Information. STELKAST will deliver to MAKO copies of all Licensed
Technical Information promptly upon the request of MAKO at any time during the Effective Period,
including without limitation relevant 510(K)s, technical files, know how, test data, product
specifications, drawings, design history files, validations, clinical data, and risk analysis
associated with current or prior unicondylar knee implant systems designed or manufactured by
STELKAST, and electronic CAD files in a standard, commercially available format containing all
manufacturing layouts and specifications for the most current version of the Implant (prostheses
and instruments) as of the Effective Date.

     3.2 Consignment of Instrumentation. STELKAST will transfer to MAKO on consignment, promptly
at its request, two complete sets of instruments for the Implant, without charge, for clinical use
by MAKO and its agents and representatives at designated sites. The instruments must include all
required instruments and trials to perform a unicondylar knee replacement procedure using the
Implant and surgical techniques used in the procedure as of the Effective Date. MAKO will have no
obligation to return the consigned sets of instruments unless the Agreement is terminated or
materially breached by MAKO and the breach is not timely cured.

     3.3 Technical Assistance. STELKAST will provide MAKO, without additional charge, technical
support during the period from the Effective Date until the date on which MAKO is able to make or
have made the Implant without the assistance of STELKAST (the “Transition Period”);
provided however that STELKAST will be relieved of any obligations under this Section 3.3 (a)
should MAKO fail to use its best efforts to minimize the duration of the Transition Period, or (b)
in any case, after the second (2nd) anniversary of the Effective Date.

     3.4 Tooling. STELKAST will use its best efforts to assist MAKO in manufacturing the Implant
in the Unites States using STELKAST’s manufacturers and tooling in existence as of the Effective
Date. Such best efforts will include, but not be limited to, making available to MAKO at no
additional cost production tooling and processes used by STELKAST as of the Effective Date.

     3.5 Clinical Training, Data and Support. Upon MAKO’s reasonable request, STELKAST will use
its best efforts to provide MAKO or its designees, without additional charge, clinical training on
surgical techniques in use as of the Effective Date for the Implant, including without limitation
access to observe clinical cases, in order to enable MAKO to support procedures using the Implant.
During the Transition Period, STELKAST will provided MAKO with clinical data and follow-ups on the
use of the Implant.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 3 

 

     3.6 FDA Approval. MAKO may sell Implants (whether purchased from STELKAST pursuant to the
Supply Agreement or made by MAKO pursuant to this License Agreement) under STELKAST’s Premarket
Notification 510(k) until MAKO receives a Premarket Notification 510(k). MAKO will use its best
effort to receive a Premarket Notification 510(k) as promptly as shall be reasonably practical
after the Effective Date. STELKAST will use its best effort, using data existing as of the
Effective Date, to assist MAKO in applying for and obtaining a Premarket Notification 510(k) and a
CE marking for the Implant by providing MAKO with all required technical information and
appropriate documentation within STELKAST’s possession or control, including, without limitation,
clinical data, a complete copy of any regulatory filing for the Implant made by STELKAST and other
relevant help at no additional charge.

ARTICLE IV.

Publicity and Confidentiality

     4.1 Confidentiality of Agreement. The terms, but not the existence, of this Agreement and the
licenses granted herein will be treated as confidential information by the Parties, and neither
Party may disclose such terms to any third party without the prior written consent of the other
Party, except as follows:

     (a) Each Party may represent to third parties that MAKO is licensed as provided by this
Agreement.

     (b) Each Party may (i) disclose this Agreement and its terms to potential acquirers of,
investors in or lenders to such Party (including any representatives of the Parties in such
transaction), or disclosures reasonably necessary in connection with the divestiture,
merger, transfer or sale of all or any portion of a Party’s respective businesses, but only
if such disclosure is made pursuant to a written confidentiality agreement binding upon such
potential acquirer, investor, lender or other parties, which obligates such party not to
disclose and to take reasonable precautions against unauthorized disclosure of the Agreement
and its terms; (ii) disclose this Agreement and its terms in any arbitration, mediation or
other official dispute resolution procedure pursuant to a written confidentiality agreement
binding upon the parties, which obligates such parties not to disclose and to take
reasonable precautions against unauthorized disclosure of the Agreement and its terms; (iii)
disclose this Agreement and its terms to its professional advisors who are under an ethical
obligation of confidentiality in order to comply with, or determine compliance with, any
law, rule, regulation, or accounting or similar requirement; and (iv) disclose this
Agreement and its terms, in response to a judicial or governmental request, requirement or
order, or as required by law, on the condition that such Party provides the other Party with
sufficient prior notice in order to contest such request, requirement or order or seek
protective measures. In addition, this Section 4.1 will not prevent a Party from making
disclosures reasonably determined by such Party to be required by law or a stock market or
exchange.

     4.2 Publicity and Trademarks. Nothing in this Agreement is intended nor shall be construed as
conferring upon either Party or its Affiliates any right to include in advertising, packaging or
other commercial activities related to the Implant, any reference to the other

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 4 

 

Party (or any of its Affiliates), its trade names, trademarks or service marks in a manner
which would be likely to cause confusion or to indicate that the Implant is in any way certified by
the other Party hereto or its Affiliates.

     4.3 Obligations of Confidentiality with Respect to Technical Information.

     (a) MAKO will hold all Licensed Technical Information provided by STELKAST to MAKO in
confidence and take reasonable precautions to maintain and protect the confidentiality of
the Licensed Technical Information. MAKO may disclose and share the Licensed Technical
Information to employees, contractors, representatives, and others who have a need to know
it, so long as each such person is obligated in writing not to disclose the information to
others and to use it only for the purposes for which access is being given. Parties other
than employees having access to the Licensed Technical Information must be licensed to use
the Licensed Technical Information, and may only use it solely in connection with the
license granted in Section 2.1.

     (b) Exceptions. Notwithstanding the foregoing obligations of confidentiality,

     (i) MAKO may make the Implant available to third parties, and all related
user documentation incorporating or made using the Licensed Technical Information.

     (ii) MAKO may disclose Licensed Technical Information as required by law, but
only to the extent required by law, and in response to a valid order of a court or
other government body or any political subdivision thereof, but only if MAKO has
promptly notified STELKAST of such order and taken reasonable action to seek a
protective order limiting the scope of the required disclosure.

     (iii) No Licensed Technical Information is required to be treated as
confidential if such information, (i) is or becomes publicly known through no
unauthorized act of MAKO or its Affiliates, (ii) is rightfully received by MAKO
from a third party without obligation of confidentiality, (iii) is approved in
writing by STELKAST for public disclosure, or (iv) was disclosed to MAKO ten years
prior.

ARTICLE V.

Payments

     5.1 License Fee. In full consideration for the license granted by STELKAST to MAKO and the
transfer of Technical information, MAKO will pay to STELKAST the sum of $[***] as follows:

     (a) $[***] previously paid by MAKO to STELKAST in connection with the LOI will be
credited to this sum upon execution of this Agreement;

     (b) $[***] upon execution of this Agreement;

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 5 

 

     (c) $[***] two months from the Effective Date or September 15, 2005, whichever is
earlier;

     (d) $[***] four months from the Effective Date or November 15, 2005, whichever is
earlier.

ARTICLE VI.

Other Obligations

     6.1 Marking. MAKO will provide appropriate labeling on the Implant as required by the Food
and Drug Administration under 21 C.F.R. Part 801.

     6.2 CE Marking Data. Should either Party desire to purchase any data generated by the other
in preparing for a CE filing, the Party with the data will sell to the other Party such data for a
fair market value, which will be negotiated by the Parties in good faith.

     6.3 Termination of LOI. The LOI and all of its obligations are hereby terminated.

ARTICLE VII.

Representations, Warranties and Covenants

     7.1 STELKAST Representations. STELKAST represents, warrants and covenants to MAKO as to the
following as of the Effective Date:

     (a) The execution, delivery and performance by STELKAST of this Agreement do not breach
any term or provision of or constitute a default under any material indenture, mortgage,
deed of trust, contract, agreement, lease or other commitment or instrument to which
STELKAST is a party or by which STELKAST or its assets or properties are bound, do not
conflict with any provision of the articles of incorporation or bylaws of STELKAST and do
not constitute an event which, with the lapse of time or action by a third party, could
result in any default under any of the foregoing.

     (b) STELKAST has full power, authority and legal right to enter into this Agreement and
grant the sublicenses and rights set forth in this Agreement and has not made, and will not
make, any commitments to others inconsistent with or in derogation of such rights. Upon
execution and delivery by STELKAST of this Agreement it will be a valid and binding
obligation of STELKAST, enforceable in accordance with its terms, except as enforcement may
be limited by bankruptcy, insolvency, reorganization or similar laws affecting the rights of
creditors generally. Notwithstanding the foregoing, no representation or warranty is made
regarding the availability of equitable remedies.

     (c) To the actual knowledge of STELKAST as of the Effective Date, the manufacture, sale
and use of the Implant and the use of Licensed Technical Information as permitted by this
Agreement, will not infringe the patents or copyrights of, or misappropriated information
of, a third party. Notwithstanding any of the foregoing in this Section 6.1(c), the failure
by STELKAST to conduct an investigation will not be

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 6 

 

deemed to be a relevant factor in any determination as to whether any warranty or
representation by STELKAST under this Section 6.1(c) is or has been breached

     (d) STELKAST has the requisite institutional knowledge and commercially adequate
expertise to provide the technical assistance and clinical support services it is offering
and/or pledging to provide to MAKO under this Agreement.

     (e) STELKAST maintains adequate insurance covering the Implant (including product
liability and commercial general liability insurance), as would be acquired and maintained
by a reasonable and prudent businessperson carrying on a similar line of business, but in no
case for an amount of less than Four Million Dollars ($4,000,000) per claim and/or
$5,000,000 in the aggregate (“Adequate Insurance”). Such Adequate Insurance shall at all
times during the Effective Period and for not less than five (5) years thereafter insure
MAKO, its Board of Directors, officers, employees, agents and consultants as insured
parties.

     7.2 MAKO Representations and Warranties. MAKO represents and warrants the following:

     (a) The execution, delivery and performance by MAKO of this Agreement do not breach any
term or provision of or constitute a default under any material indenture, mortgage, deed of
trust, contract, agreement, lease or other commitment or instrument to which MAKO is a party
or by which MAKO or its assets or properties are bound, do not conflict with any provision
of the articles of incorporation or bylaws of MAKO and do not constitute an event which,
with the lapse of time or action by a third party, could result in any default under any of
the foregoing.

     (b) MAKO has full power, authority and legal right to enter into this Agreement. Upon
execution and delivery by MAKO of this Agreement it will be a valid and binding obligation
of MAKO, enforceable in accordance with its terms, except as enforcement may be limited by
bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors
generally. Notwithstanding the foregoing, no representation or warranty is made regarding
the availability of equitable remedies.

     (c) MAKO maintains adequate insurance (including product liability and commercial
general liability insurance), as would be acquired and maintained by a reasonable and
prudent businessperson carrying on a similar line of business, but in no case for an amount
of less than Four Million Dollars ($4,000,000) per claim and/or $5,000,000 in the aggregate
(“Adequate Insurance”). Such Adequate Insurance shall at all times during the
Effective Period and for not less than five (5) years thereafter insure STELKAST, its Board
of Directors, officers, employees, agents and consultants as insured parties.

     7.3 Disclaimers.

     (a) Other than the representations, warranties and covenants expressly made in this
Agreement, neither Party, nor any of its Affiliates, make any representations or extend any
warranties of any kind, express or implied. STELKAST and MAKO each

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 7 

 

disclaim all implied warranties, including without limitation warranties of
merchantability, fitness for a particular purpose, and non-infringement.

     (b) EXCEPT IN CONNECTION WITH INDEMNIFICATION FOR DAMAGES AWARDED FOR THIRD PARTY
CLAIMS OF PERSONAL INJURY PURSUANT TO ARTICLE VIII, OR AS EXPRESSLY PROVIDED OTHERWISE IN
THIS AGREEMENT, IN NO EVENT WILL MAKO OR STELKAST BE LIABLE FOR ANY PUNITIVE, INDIRECT,
SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND WITH RESPECT TO ANY SUBJECT MATTER
OF THIS AGREEMENT UNDER ANY THEORY, INCLUDING CONTRACT, NEGLIGENCE, STRICT LIABILITY OR
OTHER LEGAL OR EQUITABLE THEORY.

ARTICLE VIII.

Indemnification

     8.1 Indemnification. STELKAST agrees to indemnify in respect of, and hold MAKO and its
officers, directors, employees and agents harmless against, any and all damages, claims,
deficiencies, losses, including taxes, and all expenses (including interest, penalties, and
reasonable attorneys’ and accountants’ fees and disbursements but reduced by any tax savings,
benefits or offsets to which MAKO shall be entitled directly or indirectly by reason thereof)
(collectively “Damages”) resulting from any misrepresentation, breach of warranty, or failure to
perform any covenant or agreement on the part of STELKAST under this Agreement. STELKAST further
agrees to indemnify in respect of, and hold MAKO and its respective officers, directors, employees
and agents harmless against, all Damages resulting from personal injuries and deaths from the use
of products manufactured, produced, sold or marketed by STELKAST or its Affiliates, except to the
extent such injury or death results from (i) the negligence, gross negligence or intentional
misconduct of MAKO and its employees, officers and directors, or any other person using the
Products, or (ii) a change made to the Product after it has been manufactured by STELKAST or the
use of a technique with respect to the Product other than a technique developed and/or endorsed by
STELKAST.

     8.2 MAKO agrees to indemnify in respect of, and hold, STELKAST and its officers, directors,
employees and agents harmless against, any and all Damages resulting from any misrepresentation,
breach of warranty, or failure to perform any covenant or agreement on the part of MAKO under this
Agreement. MAKO further agrees to indemnify in respect of, and hold STELKAST and its respective
officers, directors, employees and agents harmless against, all Damages resulting from personal
injuries and deaths from the use of any products (other than products made by STELKAST for
distribution by MAKO) manufactured, produced, sold or marketed by MAKO or its Affiliates, except to
the extent such injury or death results from the negligence, gross negligence or intentional
misconduct of STELKAST and its employees, officers and directors.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 8 

 

ARTICLE IX.

Term, Termination and Expiration

     9.1 Term. This Agreement will become effective as of the Effective Date and will continue
until terminated (the “Effective Period”) according to its terms or until expiration of all
Licensed IP Rights (the “Expiration”).

     9.2 Voluntary Termination By MAKO. MAKO may voluntarily terminate this Agreement upon 30 days
written notice to STELKAST and following payment of all sums under Article V hereto, whether such
sums are due before, on or after the effective date of such termination.

     9.3 Termination for Non-Payment. Subject to Section 9.4, failure by MAKO to make timely
payment of any amounts due and owing pursuant to Article IV shall constitute a material breach of
this Agreement and shall, after written notice by STELKAST and failure by MAKO to cure such breach
within thirty (30) days of service of such notice, render the Agreement (and any license granted
hereunder) terminable and voidable by STELKAST in its sole discretion, immediately upon written
notice to MAKO.

     9.4 Material Breach. Each Party may terminate this Agreement upon a material breach or
default by the other Party of the Agreement by giving notice to breaching party. If the material
breach or default is not cured within 60 days, the non-breaching Party may terminate this Agreement
immediately upon notice to the breaching Party..

     9.5 Survival. Articles IV, VIII and IX will survive and continue after termination of this
Agreement. Any amounts due under Articles V prior to termination will remain due and become
immediately payable upon termination. Upon termination prior to Expiration, MAKO must stop all use
of all Licensed Technical Information, except, however, that MAKO may retain and continue to use
the Licensed Technical Information for solely for purposes of supporting use of the Implant as sold
or distributed prior to termination. MAKO may also sell any inventory of the Implant ordered or on
hand prior to termination. For the avoidance of doubt, termination of this Agreement does not
affect the sale of the Implant purchased from STELKAST for resale by MAKO.

ARTICLE X.

Miscellaneous Provisions

     10.1 Assignment. STELKAST may assign this Agreement upon notice to MAKO. This Agreement
shall not be assignable by MAKO absent the written consent of STELKAST, except that no such consent
will be required for succession by merger, consolidation, sale of all or substantially all of the
assets, or change of control of MAKO, but only if the assignee, successor or surviving entity
agrees to be bound in writing to all of its terms and conditions. This Agreement will be binding
on successors in interest and permitted assigns. An assignment other than as expressly permitted
by this Section 10.1 will be void and shall constitute a material breach of this Agreement.

     10.2 Notices. All notices and other communications which are required or which may be given
under the provisions of this Agreement will be in writing and may be delivered (a) personally, (b)
by facsimile transmission, (c) expedited delivery service with proof of

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 9 

 

delivery or (d) sent by United States Mail, postage prepaid, registered or certified, return
receipt requested, addressed as follows:

	 	 	 	 	 
	 

	 	If to STELKAST:
	 	Trigon Incorporated
	 

	 	 	 	200 Hidden Valley Road
	 

	 	 	 	McMurray, PA 15317
	 

	 	 	 	Fax: (724) 941-5984
	 

	 	 	 	Attention: Peter N. Stephans
	 
	 	 	 	 
	 

	 	If to MAKO:
	 	MAKO Surgical Corp.
	 

	 	 	 	2901 Simms St.
	 

	 	 	 	Hollywood, FL 33020
	 

	 	 	 	Fax: (954) 927-0446
	 

	 	 	 	Attention: General Counsel

or to such other address designated by the Parties as provided above. Any such notice will be
deemed to have been given either at the time of personal delivery or, in the case of delivery
service or mail, as of the date of first attempted delivery at the address and in the manner
provided herein.

     10.3 Choice of Law. THIS AGREEMENT WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE
LAWS OF THE STATE OF DELAWARE, EXCLUSIVE OF ITS CONFLICTS OF LAW PRINCIPLES.

     10.4 Captions. The captions, headings, and arrangements used in this Agreement are for
convenience only and do not in any way affect, limit, amplify, or modify its terms and provisions.

     10.5 No Strict Construction. This Agreement is the result of substantial negotiations among
the Parties and their counsel and has been prepared by their joint efforts. Accordingly, the fact
that counsel to one Party or another may have drafted this Agreement, or any portion of this
Agreement, is immaterial and this Agreement will not be strictly construed against any Party.

     10.6 Severability and Reformation. Wherever possible, each provision of this Agreement will
be interpreted in such manner as to be effective. If any provision of this Agreement is held to be
illegal, invalid, or unenforceable under present or future laws effective during the term of this
Agreement, such provision will be fully severable and this Agreement will be construed and enforced
as if such illegal, invalid, or unenforceable provision had never comprised a part of this
Agreement, and the remaining provisions of this Agreement will remain in full force and effect.
Furthermore, in lieu of each such illegal, invalid, or unenforceable provision, there will be added
automatically as a part of this Agreement a provision as similar in terms to such illegal, invalid,
or unenforceable provision as may be possible and be legal, valid, and enforceable; provided,
however, that, if any such change will materially diminish the practical realization of the
benefits intended to be conferred to any Party to this Agreement, such Party may terminate this
Agreement upon written notice to the other Party within 30 days after learning such change has been
effected.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 10 

 

     10.7 Consents; Waivers. Any consent or approval required as a condition to an action under
this Agreement will be effective only (a) if in writing and signed by the Party whose consent is
sought, (b) with respect to the specific matter made the subject to such consent or approval (and
no other matter), and (c) for the specific instance(s) expressly set forth in such consent or
approval (and no earlier or subsequent instances). Any Party may waive any condition, covenant,
term, or provision of this Agreement, but any such waiver will be effective only (a) if in writing
and signed by the Party sought to be bound by such waiver, (b) with respect to the specific
condition, covenant, term, or provision expressly made the subject to such waiver (and no other
condition, covenant, term, or provision), and (c) for the specific instance(s) expressly set forth
in such waiver (and no earlier or subsequent instances). Without limiting the foregoing sentence,
none of the following will constitute a waiver of the rights of a Party to this Agreement to demand
exact compliance with the conditions, covenants, terms, and provisions of this Agreement: (a) a
failure of such Party to exercise any power reserved to it in this Agreement; (b) a failure of such
Party to insist upon compliance by any other Party to this Agreement with any condition, covenant,
term, or provision in this Agreement; (c) a delay, forbearance, or omission of such Party to
exercise any power; or (d) any custom or practice of the Parties at variance with the terms of this
Agreement. The consent or approval of any Party to this Agreement with respect to the act of any
other Party to this Agreement will not be deemed to waive or render unnecessary consent to or
approval of any subsequent similar act. Subsequent acceptance by a Party to this Agreement of any
performance due to it under this Agreement will not be deemed to be a waiver by such first Party of
any preceding breach by any other Party of any terms, provisions, covenants, or conditions of this
Agreement. No act or conduct of or by MAKO under this Agreement, including any payment of a
royalty, shall be evidence, or deemed an admission or suggestion, that any product manufactured,
licensed, or distributed by MAKO infringes the Licensed IP Rights or any other intellectual
property right.

     10.8 Force Majeure. Neither Party will be in default or otherwise liable for any delay in or
failure of its performance under this Agreement if such delay or failure arises by any reason
beyond its reasonable control, including any act of God, any acts of the common enemy, the
elements, earthquakes, floods, fires, epidemics, riots, failures or delay in transportation or
communications, or any act or failure to act by the other Party or such other Party’s employees,
agents, or independent contractors or representatives; provided, however, that lack of funds will
not be deemed to be a reason beyond a Party’s reasonable control. The Parties will promptly inform
and consult with each other as to any of the above causes that, in their judgment, may or could be
the cause of a delay in the performance of this Agreement.

     10.9 Legal Costs. Each of the Parties will be responsible for its own expenses, including
legal and accounting fees of advisors, incurred in connection with the negotiation and preparation
of this Agreement.

     10.10 Dispute Resolution.

     (a) STELKAST and MAKO will attempt to settle any claim or controversy arising out of
this Agreement through consultation and negotiation in good faith and in a spirit of mutual
cooperation.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 11 

 

     (b) In the event that, after reasonable consultation, but within 30 days, the Parties
are unable to reach agreement, any claim or controversy shall be settled by arbitration
administered by the American Arbitration Association under its then current Commercial
Arbitration Rules, before a single arbitrator and judgment on any award rendered by or
finding of the arbitrator may be entered in any court having jurisdiction thereof. The
arbitrator shall have the authority to award actual money damages (with interest on unpaid
amounts from the date due), temporary injunctive relief, and reasonable attorney’s fees and
expenses, but, the arbitrator shall not have the authority to award exemplary or punitive
damages, and the Parties expressly waive any claimed right to such damages. The costs of
arbitration shall be borne by the Parties in accordance with the award of the arbitrator.
If a Party fails to proceed with arbitration, unsuccessfully challenges the arbitration
award, or fails to comply with the arbitration award, the other Party is entitled to costs,
including reasonable attorney’s fees, for having to compel arbitration or defend or enforce
the award. Except as otherwise required by law, the Parties agree to maintain and to cause
the arbitrator to maintain as confidential all information, documents and other data of any
kind or nature whatsoever obtained during the arbitration process, including the fact that
such arbitration is being undertaken and the final award of the arbitrator.

     10.11 [INTENTIONALLY LEFT BLANK].

     10.12 Integration. This Agreement sets forth the entire agreement and understanding between
the Parties as to the subject matter hereof and merges all prior discussions between them;
provided, however, that for the avoidance of doubt, this Agreement shall not affect the
Parties’ obligations under the Supply Agreement. Neither of the Parties shall be bound
by any warranties, understandings or representations with respect to such subject matter other
than as expressly provided herein or in a writing signed with or subsequent to execution hereof by
an authorized representative of the Party to be bound thereby.

     10.13 No Partnership. Neither this Agreement, nor any terms and conditions contained herein,
will be deemed or construed to create a partnership, joint venture, other form of business
enterprise or association or cooperative arrangement, agency relationship, or franchise
relationship between the Parties or otherwise to create any liability for either Party whatsoever
with respect to the indebtedness, liabilities, and obligations of the other Party.

     10.14 Counterparts. This Agreement may be executed in any number of counterparts and will be
effective when each Party to this Agreement has executed at least one counterpart, with the same
effect as if all signing Parties had signed the same document. All counterparts will be construed
together and evidence only one agreement, which, notwithstanding the actual date of execution of
any counterpart, will be deemed to be dated the day and year first written above. In making proof
of this Agreement, it will not be necessary to account for a counterpart executed by any Party
other than the Party against whom enforcement is sought or to account for more than one
counterpart executed by the Party against whom enforcement is sought.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 12 

 

     10.15 Facsimile Signatures. The manual signature of any Party to this Agreement that is
transmitted to any other Party or counsel to any other Party by facsimile will be deemed for all
purposes to be an original signature.

     10.16 BASIS OF BARGAIN. EACH PARTY RECOGNIZES AND AGREES THAT THE WARRANTY
DISCLAIMERS AND LIABILITY AND REMEDY LIMITATIONS IN THIS AGREEMENT ARE MATERIAL, BARGAINED FOR
BASES OF THIS AGREEMENT AND THAT THEY HAVE BEEN TAKEN INTO ACCOUNT AND REFLECTED IN DETERMINING
THE CONSIDERATION TO BE GIVEN BY EACH PARTY UNDER THIS AGREEMENT AND IN THE DECISION BY EACH PARTY
TO ENTER INTO THIS AGREEMENT.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 13 

 

     IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed in duplicate
originals by its duly authorized representatives on the respective dates entered below.

	 	 	 	 	 	 	 
	 	 	TRIGON INCORPORATED	 	 
	 
	 	 	 	 	 	 
	 
	 	By:	 	/s/ Peter N. Stephans	 	 
	 
	 	Name:	 	Peter N. Stephans	 	 
	 

	 	Title:
	 	CHMN & CFO	 	 
	 

	 	Date:
	 	9/13/05	 	 
	 
	 	 	 	 	 	 
	 	 	MAKO SURGICAL CORP.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Maurice Ferré	 	 
	 

	 	Name:
	 	Maurice Ferré	 	 
	 

	 	Title:
	 	President & CEO	 	 
	 

	 	Date:
	 	9/14/05	 	 

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***].
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Page 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}]]